A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG's right to patent a new version of a lifesaving cancer drug.
The landmark ruling Monday is a victory for India's $26 billion generic drug industry that provides cheap medicines to millions around the world.
The ruling is a precedent that prevents international pharmaceutical companies from obtaining fresh patents in India on updated versions of existing drugs.
Lawyer Anand Grover said such a ruling would help poor people get access to affordable, generic versions of lifesaving medicines.
Novartis has fought a legal battle in India since 2006 for a fresh patent for a leukemia drug.
India's patent office had rejected the company's patent application because it was not a new medicine.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.